Comparative Efficacy and Safety of Moxifloxacin and Levofloxacin in a Short Standardised Rifampicin Resistant TB Regimen: A STREAM 2 Secondary Analysis

(1) Background: The World Health Organisation (WHO) categorises moxifloxacin and levofloxacin as Group A drugs, which should be prioritised in the treatment of rifampicin-resistant tuberculosis. We compare their relative efficacy and safety using data from the STREAM trial; (2) Methods: Marginal str...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Stella M. Fabiane, Chen-Yuan Chiang, Sarah K. Meredith, Meera Gurumurthy, Adamu Bayissa, Andrew J. Nunn, Ruth L. Goodall
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-09-01
coleção:	Tropical Medicine and Infectious Disease
Assuntos:	moxifloxacin levofloxacin efficacy treatment outcomes safety treatment outcomes
Acesso em linha:	https://www.mdpi.com/2414-6366/9/9/211
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!